Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Published Online: Apr 25, 2014

Page range: 184 - 188

Received: Aug 27, 2013

Accepted: Nov 18, 2013

DOI: https://doi.org/10.2478/raon-2013-0083

Keywords

breast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF

© by Robert Königsberg

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.